Clinical trial
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
NCT02270983 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
- Lead sponsor
- Forest Laboratories
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2014
- Completion date
- October 31, 2015
- Enrollment
- 254 (actual)
- Sites
- 77
Conditions
As the registry lists them; a condition with its own page is linked.